Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Dose-Ranging Study of the Effect of GS-5745 on FEV1 in Adult Subjects With Cystic Fibrosis

NCT02759562 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02759562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02759562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Dose-Ranging Study of the Effect of GS-5745 on FEV1 in Adult Subjects With Cystic Fibrosis
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Terminated
Start date
November 4, 2016
Completion date
July 21, 2017
Enrollment
6 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis